Non Invasive Prenatal Testing
Non Invasive Prenatal Testing commonly known as a 'Harmony test' is currently the leading non-invasive pregnancy screening available for parents who would like to find out if they have a low probability or high probability for their baby having the chromosomal conditions: Down’s syndrome, Edwards’ syndrome or Patau’s syndrome.
Pure Scan has collaborated with BGI to offer the detailed non invasive prenatal screening test NIFTY.
What is NIFTY?
NIFTY is a non-invasive prenatal screening test (or cell-free DNA screening) for pregnant women to assess the risk that the baby will be born with certain chromosomal abnormalities. This can be tested from as early as 10 weeks gestational age.
NIFTY is available for singleton, twin and egg donor pregnancies. It is well-trusted in more than 11,520,000 pregnancies globally, NIFTY can assess conditions that may affect your baby's health by doing a simple blood draw on you.
NIFTY screens for common chromosomal abnormalities, including trisomies, sex chromosome aneuploidies, and microdeletion/duplication syndromes, and can provide information about the sex of your babies.
According to American College of Obstetricians and Gynecologists (ACOG), cell-free DNA screening should be offered to all patients all pregnant patients regardless of maternal age or risk of chromosomal abnormality. Cell-free DNA screening is the most sensitive and specific screening test for common fetal aneuploidies1.
How does NIFTY work?
The NIFTY® test requires taking a small maternal blood sample. cfDNA in the maternal blood is then analysed with our proprietary genetic sequencing technology and bioinformatics pipelines to screen for any chromosomal abnormality. If any abnormality is present, small excesses or deficits in counts of the affected chromosome can be detected.
The technology behind the NIFTY® test allows for highly accurate results with detection rates for the three most common trisomy conditions present at birth (Down Syndrome, Edwards Syndrome and Patau Syndrome) of over 99%.
But it’s important to understand that non-invasive prenatal tests such as NIFTY® are classified as screening tests. This means that they do not test with 100% accuracy, such as with an invasive diagnostic procedure such as amniocentesis.
SUITABLE FOR: Pregnant women from week 10 of pregnancy
TA TIME: Under 7 working days
SAMPLE: Peripheral blood sample
TECHNOLOGY: Low coverage whole genome sequencing
-
Safe – no risk of miscarriage
-
Early – screen from week 10 of pregnancy
-
Fast – results delivered in under 7 working days
-
Accurate – over 99% sensitivity for trisomy conditions 21, 18 and 13
-
Trusted – over 6,000,000 samples processed worldwide, and validated on a study of over 147,000 pregnancies
NIFTY® Advantages
The most validated NIPT on the market with a published study based on the pregnancy outcomes of over 112,000 women. No other test has validation data based on such a large cohort
The only NIPT on the market to offer testing services for deletion syndromes and sex chromosome aneuploidies at no extra cost.
Largest capacity and coverage making NIFTY® price competitive against all other NIPT providers
NIFTY Indications
The NIFTY® test is suitable for, but not limited to,patients who exhibit any of the following indications
-
All maternal age of Pregnancies for screening
-
Patients should be at least 10 weeks' gestational age
-
Contraindications for invasive prenatal testing, such as placenta prevaria, risk of miscarriage, HBV infection etc.
-
History of a prior pregnancy with a chromosomal abnormality
-
Fetal ultrasonographic findings indicating an increased risk of T21, T18 or T13
-
Requires reassurance following previous screening result
-
Received IVF Treatment or has previously suffered from habitual abortion
The NIFTY® test is not suitable for patients with the following indications
-
Maternal, fetal and/ or placental mosaicism (mixtures of chromosomally normal and abnormal cells in the pregnancy)
-
Balanced or unbalanced translocation and chromosomal inversion
-
Patients who have received a blood transfusion within one year prior to testing date
-
Patients who have had transplant surgery
-
Patients who have had stem cell therapy
-
Vanishing twin syndrome (with developmental arrest identified has having occurred after week 8 of pregnancy and/or within 8 weeks of NIFTY@ testing)